2023
DOI: 10.3390/jcm12144564
|View full text |Cite
|
Sign up to set email alerts
|

Emerging Molecular Determinants and Protective Strategies in Heart Disease: What’s New in the Journal of Clinical Medicine? Outlook to the Future

Abstract: Cardiovascular diseases (CVD), including coronary heart disease (CHD), heart attacks, stroke, heart failure (HF), and peripheral artery disease, still represent the leading cause of death globally, taking an estimated 17 [...]

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

1
0

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 12 publications
0
1
0
Order By: Relevance
“…Despite the progress of pharmacological and nonpharmacological therapy in limiting and/or reversing the signs and symptoms of HF, mortality and morbidity related to this multifactorial syndrome remain elevated. Thus, identifying additional strategies to support earlier detection and treatment and deciphering key pathophysiological pathways to be targeted for achieving maximal clinical benefit in patients with HF still represents a critical medical issue [ 11 , 46 ]. The key role of the oxidoreductase SELENOT in cardiomyocyte differentiation and acute cardioprotection [ 19 , 21 , 22 ] pointed out this selenoprotein as an emerging regulator of cardiac development and function while raising an important unaddressed point concerning the beneficial action of this protein in chronic settings of cardiac dysfunction.…”
Section: Discussionmentioning
confidence: 99%
“…Despite the progress of pharmacological and nonpharmacological therapy in limiting and/or reversing the signs and symptoms of HF, mortality and morbidity related to this multifactorial syndrome remain elevated. Thus, identifying additional strategies to support earlier detection and treatment and deciphering key pathophysiological pathways to be targeted for achieving maximal clinical benefit in patients with HF still represents a critical medical issue [ 11 , 46 ]. The key role of the oxidoreductase SELENOT in cardiomyocyte differentiation and acute cardioprotection [ 19 , 21 , 22 ] pointed out this selenoprotein as an emerging regulator of cardiac development and function while raising an important unaddressed point concerning the beneficial action of this protein in chronic settings of cardiac dysfunction.…”
Section: Discussionmentioning
confidence: 99%